Printed from Voxsanity (voxsanity.com.au) — NCT04467723 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lung Cancer
Phase 2 Lung Cancer Trial, Recruiting
NCT04467723
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People aged 18 or older who have been diagnosed with non-small cell lung cancer (NSCLC), confirmed through a tissue or cell sample analysis
- People who are willing and able to follow the study schedule, including visits, treatments, and lab tests
- People, or their legal representative, who are able to sign a written consent form before any study procedures begin
- People with a life expectancy of at least 6 months
- People with stage IV NSCLC (from the start or returned after earlier treatment) that does not have certain specific gene mutations (such as EGFR, ALK, or ROS-1), and who have previously been treated with immunotherapy (PD-1/PD-L1) or immunotherapy combined with chemotherapy, with no more than 2 prior treatment courses for advanced disease
- People with early-stage NSCLC (stages I–III) who received chemotherapy before or after surgery, and then received immunotherapy when the cancer came back
- People with stage III NSCLC that could not be removed surgically, who were treated with chemotherapy and radiation followed by ongoing immunotherapy, and whose cancer can be measured on scans
- People whose PD-L1 score is either below 1% or unknown, and whose first treatment included immunotherapy combined with chemotherapy
- People with at least one area of cancer that can be measured on scans
- People who are able to swallow tablets or capsules
- People with adequate blood counts and organ function (confirm with trial site)
- People with a general physical ability score of 0, 1, or 2 on the ECOG scale, meaning they are fully active to being up and about more than half of waking hours (confirm with trial site)
- People with a previous history of a different cancer, as long as that cancer has not been actively treated within the past year
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who are pregnant or breastfeeding
- People with a known allergic reaction to atezolizumab or pirfenidone
- People who have taken another experimental treatment within 14 days, or within 5 half-lives of that drug (whichever is longer), before the first dose of this trial's treatment
- People with another serious or uncontrolled medical condition that a doctor believes would make participation unsafe
- People with active mental or physical health conditions that could interfere with treatment
- People with uncontrolled diabetes
- People with certain heart conditions, including unstable chest pain (angina), a heart attack within the past 6 months, uncontrolled heart failure, or a significantly reduced heart pumping function (ejection fraction below 35%)
- People who had a severe (grade 3 or 4) reaction to a prior immunotherapy treatment
- People with HIV that is not well controlled
- People diagnosed with moderate to severe radiation-related lung injury (grade 2 or 3) within the past 3 months
- People with a history of lung inflammation of unknown cause (idiopathic pneumonitis) that required treatment with steroids or other systemic medicines
- People with lung inflammation caused by a medication (drug-induced pneumonitis)
- People with signs of active lung inflammation showing on a CT scan at the time of screening
- People who smoke more than one pack of cigarettes per day
- People with an active stomach ulcer diagnosed within the past 4 weeks
- People with an active infection that requires treatment with medicines taken throughout the body (systemic treatment)
- People currently taking systemic antibiotics or antifungal medicines
- People who have received a monoclonal antibody treatment within 4 weeks before the study start date (note: denosumab is an exception to this rule)
- People who have not recovered from side effects of prior treatments to a mild level (grade 1 or lower)
- People currently taking part in another clinical trial with an experimental treatment
- People with brain or spinal fluid spread of cancer (brain metastases or leptomeningeal disease) that is uncontrolled or causing symptoms and requires steroid treatment
- People taking strong medications that significantly affect how a specific liver enzyme (CYP1A2) processes drugs (confirm with trial site)
- People with another cancer that has been actively treated within the past year
- People with active autoimmune diseases
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Contact this trial
Principal Investigator: Chao Huang, MD, The University of Kansas
Phone: 9135883671
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 2
Sponsor
University of Kansas Medical Center
Registry
ClinicalTrials.gov
Start date
18 May 2022
Est. completion
1 January 2027
Where this trial is recruiting
🇺🇸 United States
Primary endpoints
Occurrence of Grade 3 toxicity; Occurrence of Grade 4 toxicity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.